Throughout the majority of the last century, anesthesiology research primarily focused on physiologic phenomena within the time window of the intraoperative and immediate postoperative period (1). During the last two decades, the spectrum of interest has broadened to include intermediate and long-term effects of anesthesia-related interventions (1). Examples of this evolution include large clinical trials evaluating the impact of cardiovascular drugs on 30-day major cardiovascular outcomes (2-4) and the impact of anesthesia techniques on cancer recurrence in the years after surgery (5-7). Major cardiovascular complication occurred in 1.4% (95% CI 1.0-1.8%) of patients older than 50 years hospitalized for elective noncardiac surgery at 30 days (2). Conservative estimates (8) suggest that at least half of the 200 million adults undergoing non-cardiac surgery are in an at-risk age group (9). This suggests that worldwide 1-1.8 million adults suffer a major perioperative vascular complication annually. There is concern, however, that this data substantially underestimate the current incidence. In a recent large international randomized controlled study conducted in 190 hospital in 23 countries, 6.9% of patients over 45 years, with or at risk of cardiovascular disease, hospitalized for noncardiac surgery (both elective and urgent) suffered a cardiovascular event within 30 days (10). This implies that the current worldwide incidence of adults suffering a major perioperative vascular complication in the first 30 days after surgery is probably in the range of 3-5.4 million annually. The research tools to tackle the enormous global burden of perioperative cardiovascular complications by rigorous research are different from the ones we have primarily used for intraoperative anesthesiology research. The change in the spectrum of the research question
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requires a change in research methods and research culture. Given the well known errors associated with the extrapolation of physiologic variables to clinical effects (11) , there is a need to move from physiology to endpoints suitable to answer the new questions we are asking, i.e. patient-important outcomes (12) . Perioperative myocardial infarction, stroke,death, and other perioperative patient-important outcomes share two common traits. In unselected adult perioperative populations these events will occur in less than 10% of patients and they are mediated through multiple pathways. These two points have substantial implications for the required sample size to ensure a reliable study result. The appropriate change in focus from a dichotomous surrogate outcome that occurs in 20% of the control patients to a patient-important outcome developing in 5% of the patients will increase the planned sample size (chi-squared, alpha 0.05, power 80%, estimated relative risk reduction 50%), from 450 to round 2,000 patients. This however, is only half of the truth. The calculation assumed a relative risk reduction of 50%. This assumption becomes unwarranted by the substitution of a surrogate endpoint, ideally related to the beneficial effect of the intervention by a direct mechanism, to a patient-important outcome mediated by multiple pathways (13) . The multiple pathways leading to the outcome make it implausible that any single intervention, which targets no more than a few mechanisms, will have a large effect. The intervention will achieve a moderate effect in the range of 10-30% (13). Therefore, optimistically assuming a 25% relative risk reduction, the sample size required to assess a patient-important outcome occurring in 5% of the controls, will be round 9,000 patients. The conduct of trials enrolling several thousand perioperative patients is beyond a realistic expectation of any single institution or even most nations. This calls for the development of international perioperative research collaborations. Tackling the large global burden of perioperative cardiovascular events after non-cardiac surgery requires large global trials. These trials are starting to happen and the perioperative culture is starting to embrace large international trials.
• Methodology and basic statistics • Impact Factor, H index, Scopus, Pubmed and Google Scholar • The point of view of the author, reviewer, editor • How to review a paper • Without publication your discoveries will remain in your laboratory or in your ward and will be unknown to the rest of the biomedical community. Remember that it is your duty to contribute to the construction of an ever-growing biomedical database that will hopefully develop clinical and surgical techniques, therefore improving the health and lives of your patients.
• How is it possible to be captivating and interesting when communicating scientifi c data? Science is serious, but there is no reason why it should be boring. 
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